Targets › FCAR
2 programs from 2 companies in 2 trials: 2 Phase 2; Neurology, Genitourinary; next expected readout Aug 2028.
Binds to the Fc region of immunoglobulins alpha. Mediates several functions including cytokine production. (UniProt, P24071)
Open in Phaseline: the race on FCAR, likelihood bands and readouts
| Company | Drug | Targets | Highest phase | Conditions | Next expected readout |
|---|---|---|---|---|---|
| Immunovant Sciences | Imeroprubart FcγRIIB-FcαRI fusion protein; neonatal Fc receptor (FcRn) inhibitor | FCAR | Phase 2 | Chronic Inflammatory Demyelinating Polyneuropathy | Aug 2028 |
| argenx | ARGX-121 IgA immune complex inhibitor; blocks FcαRI signaling pathway | FCAR | Phase 2 | Immunoglobulin A Nephropathy (IgAN) | Oct 2029 |
Chronic Inflammatory Demyelinating Polyneuropathy (1) Immunoglobulin A Nephropathy (IgAN) (1)
antibody (1), protein or peptide (1)
Programs group each company's trials by drug; targets and mechanisms come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood is in the app.